Evidence-based management of ulcerative colitis

Minerva Gastroenterologica e Dietologica

Volumn 58, Issue 2, 2012, Pages 87-99

  Gracie, D J ^a   Ford, A C ^a,b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Aminosalicylic acid; Colitis, ulcerative; Cyclosporine infliximab

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; RITUXIMAB;

APHERESIS; COLON RESECTION; DISEASE ACTIVITY; EVIDENCE BASED MEDICINE; HUMAN; ILEAL POUCH ANAL ANASTOMOSIS; INTESTINE ANASTOMOSIS; PREVALENCE; RELAPSE; REMISSION; REVIEW; ULCERATIVE COLITIS;

ACUTE DISEASE; CHRONIC DISEASE; COLITIS, ULCERATIVE; EVIDENCE-BASED MEDICINE; HUMANS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 84864744687     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Loftus Jr EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitisin Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000;46:336-43.
2. Loftus CG, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13:254-261.
3. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5:1424-9.
4. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963;4:299-315.
5. Watts JM, De Dombal FT, Watkinson G, Goligher JC. Long-term prognosis of ulcerative colitis. Br Med J 1966;1:1447-53.
6. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:590-9.
7. Angus P, Snook JA, Reid M, Jewell DP. Oral fluticasone propionate in active distal ulcerative colitis. Gut 1992;33:711-4.
8. Bossa F, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol 2008;103:2509-16.
9. Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CWE, Avery Jones F. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960;1:217-22.
10. Rizzello F, Gionchetti P, D'Arienzo A, Manguso F, Di Matteo G, Annese V et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002;16:1109-16.
11. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955;2:1041-8.
12. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
13. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Dornizio P et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
14. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7.
15. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
16. Probert CJ, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott IDR et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002.
17. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
18. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-8.
19. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59.
20. Gustavsson A, Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2011;32:984-9.
21. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;CD004277.
22. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
23. D'Haens G, Lemmens L, Geboes K, Vandeputte L, van Acker F, Mortelmans L et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9.
24. Leiper K, Martin K, Ellis A, Subramanian S, Watson AJ, Christmas SE et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011;60:1520-6.
25. Baron JH, Connell AM, Lennard-Jones JE, Avery Jones F. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962;1:1094-6.
26. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964;5:437-42.
27. Hetzel DJ, Shearman DJC, Bochner F, Imhoff DM, Gibson GE, Hecker R et al. Azodisalicylate (olsalazine) in the treatment of active ulcerative colitis. A placebo controlled trial and assessment of drug disposition. J Gastroenterol Hepatol 1986;1:257-66.
28. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
29. Miner P, Nostrant T, Wruble L, Hines C, Johnson S, Wilkinson C et al. Multicenter trial of Pentasa for active ulcerative colitis. Gastroenterology 1991;100(suppl):A231.
30. Sninsky CA, Cort DH, Shanahan F, Powers BJ, Sessions JT, Pruitt RE et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. Ann Intern Med 1991;115:350-5.
31. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993;88:1188-97.
32. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132:66-75.
33. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95-102.
34. Schert EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S et al. Safety and efficacy of a new 3.3g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2009;104:1452-9.
35. Ito H, Iida M, Matsumoto T, Suzuki Y, Sasaki H, Yoshida T et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind randomized study. Inflamm Bowel Dis 2010;16:1567-74.
36. Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, Marshall JK et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011;106:601-16.
37. Miglioli M, Bianchi Porro G, Brunetti G, Sturniolo GC. Delayed release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. Eur J Gastroenterol Hepatol 1990;2:229-34.
38. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478-85.
39. D'Haens G, Hommes D, Engels L, Baert F, van der Waai L, Connor P et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006;24:1087-97.
40. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacshyn B, Yeh C et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007;21:827-34.
41. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009;137:1934-43.
42. Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D et al. A randomized, double blind, dose-response comparison of balsalazide (6.75g), balsalazide (2.25g), and mesalamine (2.4g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398-407.
43. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988;29:669-74.
44. Kruis W, Bar-Meir S, Feher J, Mickisch O, Mutz H, Faszczyk M et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003;1:36-43.
45. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;CD004115.
46. Ford AC, Khan KJ, Achkar J-P, Moayyedi P. Efficacy of oral versus topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2012;107:167-76.
47. Kam L, Cohen H, Dooley C, Rubin P, Orchard J. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996;91:1338-42.
48. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867-71.
49. Gionchetti P, Rizzello F, Venturi A, Ferretti M, Brignola C, Miglioli M et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998;41:93-7.
50. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005;11:421-7.
51. Fruhmorgen P, Demling L. On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid, and descending colon. Hepatogastroenterology 1980;27:473-6.
52. Vecchi M, Meucci G, Gionchetti P, Beltrami M, Di Maurizio P, Beretta L et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001;15:251-6.
53. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind placebo controlled study. Gut 2005;54:960-5.
54. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40:775-81.
55. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974;4:627-30.
56. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000;19:14-6.
57. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:630-42.
58. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21.
59. Misiewicz JJ, Lennard-Jones JE, Conneli AM, Baron JH, Avery Jones F. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-7.
60. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut 1973;14:923-6.
61. Riis P, Anthonisen P, Wulff HR, Folkenborg O, Bonnevie O, Binder V. The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year. Scand J Gastroenterol 1973;8:71-4.
62. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology 1986;90:1024-30.
63. Lauritsen K, Staerk Laursen L, Bukhave K, Rask-Madsen J. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut 1988;29:1316-21.
64. Wright JP, O'Keefe EA, Cuming L, Jaskiewicz K. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci 1993;38:1837-42.
65. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S, and Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995;40:296-304.
66. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. Ann Intern Med 1996;124:204-11.
67. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF, and the European Zileuton Study Group for ulcerative colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 1997;112:718-24.
68. Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 1999;13:373-9.
69. Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. Aliment Pharmacol Ther 2010;32:990-9.
70. Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980;21:232-40.
71. Green JRB, Swan CHJ, Rowlinson A, Gibson JA, Brown P, Kerr GD et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992;6:647-52.
72. Travis SPL, Tysk C, de Silva HJ, Sandberg-Gertzen H, Jewell DP, Jarnerot G. Optimum dose of olsalazine for maintaining remission of ulcerative colitis. Gut 1994;35:1282-6:
73. Fockens P, Mulder CJJ, Tytgat GNJ, Blok P, Ferwerda J, and the Dutch Pentasa Study Group. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:1025-30.
74. Kruis W, Schreiber S, Theuer D, Brandes JW, Schutz E, Howaldt S et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001;49:783-9.
75. Paoluzi OA, Iacopini F, Pica R, Crispino P, Marcheggiano A, Consolazio A et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005;21:1111-9.
76. Kruis W, Jonaitis L, Pokrotniets J, Mikhailova TL, Horynski M, Batovsky M et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;33:313-22.
77. Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011;106:2070-7.
78. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Borner N et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:762-9.
79. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC et al. Once daily Asacol in maintenance therapy for ulcerative colitis: a one-year single-blind randomised trial. Gut 2011;60 (suppl 1):A37-A38.
80. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K et al. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57:893-902.
81. Kane S, Holderman W, Jacques P, Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Prefer Adherence 2008;2:253-8.
82. Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009;30:908-18.
83. Sandborn WJ, Korzenik J, Lashner B, Leighton J, Mahadevan U, Marion JF et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010;138:1286-96.
84. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
85. Travis SPL, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2:24-62.
86. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-76.
87. Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol 2011 [Epub ahead of print].
88. D'Albasio G, Pacini F, Camarri E, Messori A, Trallori G, Bonanomi AG et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997;92:1143-7.
89. Hanauer S, Good LI, Goodman M, Pizinger RJ, Strum WB, Lyss C et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance in ulcerative colitis. Am J Gastroenterol 2000;95:1749-54.
90. Biddle WL, Greenberger NJ, Swan JT, McPhee MS, Miner PB. 5-aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988;94:1075-9.
91. D'Arienzo A, Panarese A, D'Armiento FP, Lancia C, Quattrone P, Giannattasio F et al. 5-aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990;85:1079-82.
92. D'Albasio G, Paoluzi P, Campieri M, Bianchi Porro G, Pera A, Prantera C et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. Am J Gastroenterol 1998;93:799-803.
93. Marteau P, Crand J, Foucault M, Rambaud JC. Use of mesalazine slow release suppositories 1g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998;42:195-9.
94. Miner P, Daly R, Nester T, and the Rowasa Study Group. The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis. Gastroenterology 1994;106(suppl 2):A736.
95. D'Albasio G, Trallori G, Ghetti A, Milla M, Nucci A, Pacini F et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990;33:394-7.
96. Andreoli A, Spinella S, Levenstein S, Prantera C. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis. Ital J Gastroenterol 1994;26:121-5.
97. Mantzaris GJ, Hatzis A, Petraki K, Spiliadi C, Triantaphyllou G. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 1994;37:58-62.
98. Yokoyama H, Takagi S, Kuriyama S, Takahashi S, Takahashi H, Iwabuchi M et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007;13:1115-20.
99. Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenace of remission in severe ulcerative colitis. J Gastroenterol 2002;37:270-4.
100. National Institute for Health and Clinical Excellence. Infliximab for subacute manifestations of ulcerative colitis [Internet]. Available at http://www.nice.org.uk/nicemedia/live/11959/40412/40412 [cited 2012, Mar 6].
101. Thanaraj S, Hamlin PJ, Ford AC. Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. Aliment Pharmacol Ther 2010;32:1297-306.
102. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004;70:36-44.
103. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyma Y, Kageoka M et al. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008;40:433-40.
104. Nakamura T, Kawagoe Y, Matsuda T, Ueda A, Ueda Y, Takahashi Y et al. Effect of granulocyte and monocyte adsorption apheresis on urinary albumin excretion and plasma endothelin-1 concentration in patients with active ulcerative colitis. Blood Purif 2004;22:499-504.
105. Shimoyama T, Sawada K, Tanaka T, Saito Y, Munakata A, Toyota T et al. Granulocyte and monocyte apheresis with the G-1 column in the treatment of patients with active ulcerative colitis. Jpn J Apher 1999;18:117-31.
106. Sands BE, Sandborn WJ, Feagan BG, Lofberg R, Hibi T, Wang T et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135:400-9.